BaldaniG. Regolamentare l'infinito: La sfida della Food and Drug Administration. AngeliF (ed.). Rome, Italy: Salute e Società, 2014:171–175.
2.
PalozziAM, GiovagnoliMR, GiansantiD. Towards the testing of Whatsapp for Digital Cytology Teleconsulting, GNB 2016. Naples: e-Book, 2016:543–545.
3.
CensiF, MatteiE, TriventiM, CalcagniniG. Regulatory frameworks for mobile medical applications. Expert Rev Med Devices, 2015; 12:273–278.
4.
Collado-BorrellR, Escudero-VilaplanaV, Ribed-SánchezA, Ibáñez-GarcíaS, Herranz-AlonsoA, Sanjurjo-SáezM. Smartphone applications for cancer patients; what we know about them?. Farm Hosp, 2016; 40:25–35.
5.
EgbringM, FarE, RoosM, DietrichM, BrauchbarM, Kullak-UblickGA, TrojanA. A mobile app to stabilize daily functional activity of breast cancer patients in collaboration with the physician: A randomized controlled clinical trial. J Med Internet Res, 2016; 18:e23.
6.
KimJ, LimS, MinYH, ShinYW, LeeB, SohnG, JungKH, LeeJH, SonBH, AhnSH, ShinSY, LeeJW. Depression screening using daily mental-health ratings from a smartphone application for breast cancer patients. J Med Internet Res, 2016; 18:e216.
7.
CoughlinSS, ThindH, LiuB, WilsonLC. Towards research-tested smartphone applications for preventing breast cancer. M-health, 2016; 2:26.
8.
SmithSA, WhiteheadMS, SheatsJ, MastromonicoJ, YooW, CoughlinSS. A community-engaged approach to developing a mobile cancer prevention app: The mCPA study protocol. JMIR Res Protoc, 2016; 5:e34.